Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226392 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 704
- Enrollment target
NCT03226392 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 704 participants.
The verdict
NCT03226392, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 704 participants
- Enrollment target
Study Summary
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent (≥ 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second (FEV1) at the end of 12 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG QAW039
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 704 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226392
The ClinicalTrials.gov registry entry for NCT03226392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 704 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03226392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03226392 about?
NCT03226392 is a clinical study titled "Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma". A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent (≥ 12 years) patients with uncontrolled asthma with respect to change f...
What is the current status of trial NCT03226392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 704 participants. The study started on 2017-10-31. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT03226392?
The interventions under investigation include: Placebo (DRUG), QAW039 (DRUG).
Who is sponsoring clinical trial NCT03226392?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.